Events

European IP Helpdesk webinar: IP in EU funded projects with a special focus on MSCA
NOV
Thu
07
10:30 - 12:00

This was 1 year ago

Location

virtual

Programmes
MSCA

This webinar hosted by the European IP Helpdesk will provide an overview of key aspects in the field of intellectual property management in Marie Skłodowska-Curie Actions (MSCA) and offers a Q&A. the webinar covers the following topics:

  • Relevant IP issues for MSCA proposals
  • Particularities of MSCA grant agreements
  • Ownership of background and results
  • Questions from MSCA participants received at the European IPR Helpdesk
  • MSCA success stories

The registration form is available in the announcement of the webinar on the European IP Helpdesk website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.